Brief: Mateon Therapeutics Submitted Application To FDA To Study Investigational Drug For Treatment Of Covid-19
27/04/2020 13:28
April 27 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON THERAPEUTICS - SUBMITTED IND APPLICATION TO U.S.
FDA TO
STUDY ITS INVESTIGATIONAL DRUG, OT-101, FOR TREATMENT OF
COVID-19 PANDEMIC
* MATEON THERAPEUTICS - PROPOSED RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED PHASE 2 STUDY INTENDED TO EVALUATE SAFETY,
EFFICACY OF OT-101 IN ADULT PATIENTS HOSPITALIZED WITH COVID-19
& PNEUMONIA IN U.S.
Source text for Eikon: ID:nGNX45dhf8
Further company coverage: MATN.PK
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas